Skip to main content
Log in

A biological drug that is superior to Boehringer Ingelheim/Pfizer's roflumilast [Spiriva] in reducing COPD exacerbations would earn a higher patient share in Europe

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. Decision Resources.A Biologic Drug Superior to Spiriva in Reducing COPD-Related Exacerbations Would Earn a Higher Patient Share in Europe Than in the U.S. Media Release: 12 Jan 2009. Available from: URL: http://www.decisionresosurces.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

A biological drug that is superior to Boehringer Ingelheim/Pfizer's roflumilast [Spiriva] in reducing COPD exacerbations would earn a higher patient share in Europe. Pharmacoecon. Outcomes News 570, 10 (2009). https://doi.org/10.2165/00151234-200905700-00031

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905700-00031

Keywords

Navigation